Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
non squamous - mNSCLC - L1 - all population, atezolizumab plus carboplatin plus nab-paclitaxel vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMpower-130 (all population), 2019 (REV) 1.25 [1.01; 1.54]
1.25 [1.01 ; 1.54 ] IMpower-130 (all population), 2019 (REV) 1 0% 723 NA not evaluable progression or deaths (PFS)detailed results IMpower-130 (all population), 2019 (REV) 1.54 [1.29; 1.84]
1.54 [1.29 ; 1.84 ] IMpower-130 (all population), 2019 (REV) 1 0% 723 NA not evaluable AE (any grade)detailed results IMpower-130 (all population), 2019 (REV) 0.49 [0.07; 3.49]
0.49 [0.07 ; 3.49 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.58 [0.41; 0.84]
0.58 [0.41 ; 0.84 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable AE leading to death (grade 5)detailed results IMpower-130 (all population), 2019 (REV) 1.06 [0.53; 2.12]
1.06 [0.53 ; 2.12 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results IMpower-130 (all population), 2019 (REV) 0.78 [0.54; 1.14]
0.78 [0.54 ; 1.14 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable SAE (any grade)detailed results IMpower-130 (all population), 2019 (REV) 0.59 [0.43; 0.82]
0.59 [0.43 ; 0.82 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable STRAE (any grade)detailed results IMpower-130 (all population), 2019 (REV) 0.48 [0.31; 0.74]
0.48 [0.31 ; 0.74 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable TRAE (any grade)detailed results IMpower-130 (all population), 2019 (REV) 0.50 [0.25; 0.99]
0.50 [0.25 ; 0.99 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.56 [0.40; 0.78]
0.56 [0.40 ; 0.78 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable TRAE leading to death (grade 5)detailed results IMpower-130 (all population), 2019 (REV) 0.25 [0.03; 2.02]
0.25 [0.03 ; 2.02 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Alopecia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 2.04 [0.04; 103.19]
2.04 [0.04 ; 103.19 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Anaemia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.62 [0.42; 0.90]
0.62 [0.42 ; 0.90 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Asthenia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.68 [0.18; 2.52]
0.68 [0.18 ; 2.52 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Constipation TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 1.02 [0.03; 30.50]
1.02 [0.03 ; 30.50 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 1.17 [0.34; 4.03]
1.17 [0.34 ; 4.03 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.97 [0.47; 2.03]
0.97 [0.47 ; 2.03 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Dysgeusia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 2.04 [0.04; 103.19]
2.04 [0.04 ; 103.19 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Fatigue TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.98 [0.51; 1.90]
0.98 [0.51 ; 1.90 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Nausea TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.62 [0.20; 1.93]
0.62 [0.20 ; 1.93 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.82 [0.58; 1.16]
0.82 [0.58 ; 1.16 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.66 [0.36; 1.21]
0.66 [0.36 ; 1.21 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Vomiting TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.68 [0.18; 2.52]
0.68 [0.18 ; 2.52 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 1.02 [0.03; 30.50]
1.02 [0.03 ; 30.50 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Abdominal pain AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.81 [0.16; 4.23]
0.81 [0.16 ; 4.23 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Agranulocytosis (AE grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 4.09 [0.14; 122.39]
4.09 [0.14 ; 122.39 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Alopecia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 2.04 [0.04; 103.19]
2.04 [0.04 ; 103.19 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Anaemia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.68 [0.47; 0.97]
0.68 [0.47 ; 0.97 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Arthralgia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.13 [0.01; 2.20]
0.13 [0.01 ; 2.20 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Asthenia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.63 [0.23; 1.74]
0.63 [0.23 ; 1.74 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Back pain AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.25 [0.03; 2.02]
0.25 [0.03 ; 2.02 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Blood creatinine increased AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.51 [0.02; 11.32]
0.51 [0.02 ; 11.32 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Colitis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.34 [0.02; 6.78]
0.34 [0.02 ; 6.78 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Constipation AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.20 [0.01; 3.72]
0.20 [0.01 ; 3.72 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Cough AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.34 [0.02; 6.78]
0.34 [0.02 ; 6.78 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Decreased appetite AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 1.02 [0.34; 3.02]
1.02 [0.34 ; 3.02 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Diabetes mellitus AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.51 [0.02; 11.32]
0.51 [0.02 ; 11.32 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Diarrhoea AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 1.15 [0.59; 2.26]
1.15 [0.59 ; 2.26 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Dizziness AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 2.04 [0.13; 32.81]
2.04 [0.13 ; 32.81 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Dry skin AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 4.09 [0.14; 122.39]
4.09 [0.14 ; 122.39 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Dysgeusia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 2.04 [0.04; 103.19]
2.04 [0.04 ; 103.19 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Dyspnoea AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.18 [0.04; 0.76]
0.18 [0.04 ; 0.76 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Epistaxis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 2.04 [0.13; 32.81]
2.04 [0.13 ; 32.81 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Fatigue AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.78 [0.41; 1.48]
0.78 [0.41 ; 1.48 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Febrile neutropenia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 1.12 [0.41; 3.05]
1.12 [0.41 ; 3.05 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Gastritis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.51 [0.02; 11.32]
0.51 [0.02 ; 11.32 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Headache AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 1.02 [0.03; 30.50]
1.02 [0.03 ; 30.50 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Hypertension AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.68 [0.14; 3.38]
0.68 [0.14 ; 3.38 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Hyperthyroidism AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 2.04 [0.13; 32.81]
2.04 [0.13 ; 32.81 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.51 [0.02; 11.32]
0.51 [0.02 ; 11.32 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Increase AST AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 1.02 [0.25; 4.11]
1.02 [0.25 ; 4.11 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Increased ALT AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 1.37 [0.38; 4.89]
1.37 [0.38 ; 4.89 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Infusion-related reaction AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 1.02 [0.03; 30.50]
1.02 [0.03 ; 30.50 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Leucopenia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.64 [0.27; 1.52]
0.64 [0.27 ; 1.52 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Myalgia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 1.02 [0.03; 30.50]
1.02 [0.03 ; 30.50 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Nausea AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.63 [0.23; 1.74]
0.63 [0.23 ; 1.74 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Neutropenia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.81 [0.57; 1.14]
0.81 [0.57 ; 1.14 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Pancytopenia (AE grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 2.05 [0.29; 14.63]
2.05 [0.29 ; 14.63 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Paraesthesia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.51 [0.02; 11.32]
0.51 [0.02 ; 11.32 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Peripheral neuropathy AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 1.36 [0.23; 8.21]
1.36 [0.23 ; 8.21 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 1.36 [0.23; 8.21]
1.36 [0.23 ; 8.21 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Peripheral sensory neuropathy AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 1.02 [0.25; 4.11]
1.02 [0.25 ; 4.11 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Pneumonia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.72 [0.34; 1.50]
0.72 [0.34 ; 1.50 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Pneumonitis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 4.09 [0.14; 122.39]
4.09 [0.14 ; 122.39 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Pruritus AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 1.02 [0.03; 30.50]
1.02 [0.03 ; 30.50 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Pyrexia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 1.02 [0.03; 30.50]
1.02 [0.03 ; 30.50 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Rash AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 1.02 [0.09; 11.30]
1.02 [0.09 ; 11.30 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Rash maculopapular AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 1.02 [0.03; 30.50]
1.02 [0.03 ; 30.50 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Sepsis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.14 [0.01; 2.54]
0.14 [0.01 ; 2.54 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Stomatitis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 4.10 [0.37; 45.50]
4.10 [0.37 ; 45.50 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.67 [0.37; 1.21]
0.67 [0.37 ; 1.21 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Vomiting AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 0.78 [0.27; 2.21]
0.78 [0.27 ; 2.21 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable Weight decreased AE (grade 3-4)detailed results IMpower-130 (all population), 2019 (REV) 1.02 [0.09; 11.30]
1.02 [0.09 ; 11.30 ] IMpower-130 (all population), 2019 (REV) 1 0% 705 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-11-01 00:15 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 165
- treatments: 865